Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Lung Cancer Therapy Market Share Worth $80.49 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
November 01, 2023 06:46 ET
|
The Insight Partners
Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly...
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
October 13, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL...
Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031, rising at a 11.9% CAGR: TMR Report
May 05, 2023 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global small cell lung cancer therapeutics market was valued at USD 4.6 Bn in 2022 and is projected to expand at a CAGR of...
USD 12.6 Bn Cancer Biomarkers Market to Grow at a CAGR of 9.9% During 2022 to 2031 - Global Analysis by Transparency Market Research
April 26, 2023 06:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 26, 2023 (GLOBE NEWSWIRE) -- According to Transparency Market Research, tThe global cancer biomarkers market size stood at USD 12.6 Bn in 2021. The market...
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
April 04, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal...
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
January 11, 2023 07:10 ET
|
Syneos Health, Inc.
MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with...
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
June 21, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported...
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
May 02, 2022 09:00 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...